Initial experience of endoscopic ultrasound-guided antegrade covered stent placement with long duodenal extension for malignant distal biliary obstruction (with video).
EUS-guided biliary drainage
Endoscopic ultrasound
duodenal obstruction
malignant biliary obstruction
surgically altered anatomy
Journal
Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
revised:
21
05
2021
received:
22
01
2021
accepted:
31
05
2021
pubmed:
13
6
2021
medline:
29
12
2021
entrez:
12
6
2021
Statut:
ppublish
Résumé
This study aimed to evaluate the feasibility of endoscopic ultrasound (EUS)-guided antegrade covered stent placement with long duodenal extension (EASL) for malignant distal biliary obstruction (MDBO) with duodenal obstruction (DO) or surgically altered anatomy (SAA) after failed endoscopic retrograde cholangiopancreatography (ERCP). Outcomes were technical and clinical success, reintervention rate, adverse events, stent patency, and overall survival. Inverse probability of treatment weighting (IPTW) and competing-risk analysis were performed to compare with conventional EUS-BD. Twenty-five patients (DO, n = 18; SAA, n = 7) were included. The technical and clinical success rates were 96% and 84%, respectively. Reintervention occurred in two patients (8.3%). Adverse events occurred in six patients (24%; two cholangitis, 16%; four mild postprocedural pancreatitis [24% (n = 4/17) in patients with non-pancreatic cancers]). The median patency was 9.4 months, and the overall survival was 2.73 months. After IPTW adjustment, the median patency in the EASL (n = 25) and conventional EUS-BD (n = 29) were 10.1 and 6.5 months, respectively (P = .018). EASL has acceptable clinical outcomes with a low reintervention rate but higher rate of postprocedural pancreatitis in patients with non-pancreatic cancers. Randomized trials comparing EASL and conventional EUS-BD for MDBO with pancreatic cancers and DO/SAA after failed ERCP are needed to validate our findings.
Sections du résumé
BACKGROUND/PURPOSE
OBJECTIVE
This study aimed to evaluate the feasibility of endoscopic ultrasound (EUS)-guided antegrade covered stent placement with long duodenal extension (EASL) for malignant distal biliary obstruction (MDBO) with duodenal obstruction (DO) or surgically altered anatomy (SAA) after failed endoscopic retrograde cholangiopancreatography (ERCP).
METHODS
METHODS
Outcomes were technical and clinical success, reintervention rate, adverse events, stent patency, and overall survival. Inverse probability of treatment weighting (IPTW) and competing-risk analysis were performed to compare with conventional EUS-BD.
RESULTS
RESULTS
Twenty-five patients (DO, n = 18; SAA, n = 7) were included. The technical and clinical success rates were 96% and 84%, respectively. Reintervention occurred in two patients (8.3%). Adverse events occurred in six patients (24%; two cholangitis, 16%; four mild postprocedural pancreatitis [24% (n = 4/17) in patients with non-pancreatic cancers]). The median patency was 9.4 months, and the overall survival was 2.73 months. After IPTW adjustment, the median patency in the EASL (n = 25) and conventional EUS-BD (n = 29) were 10.1 and 6.5 months, respectively (P = .018).
CONCLUSIONS
CONCLUSIONS
EASL has acceptable clinical outcomes with a low reintervention rate but higher rate of postprocedural pancreatitis in patients with non-pancreatic cancers. Randomized trials comparing EASL and conventional EUS-BD for MDBO with pancreatic cancers and DO/SAA after failed ERCP are needed to validate our findings.
Identifiants
pubmed: 34118136
doi: 10.1002/jhbp.1011
pmc: PMC9290461
doi:
Types de publication
Journal Article
Video-Audio Media
Langues
eng
Sous-ensembles de citation
IM
Pagination
1130-1137Subventions
Organisme : Korea Medical Device Development Fund
ID : KMDF_PR_20200901_0266
Organisme : Korea Medical Device Development Fund
ID : 999100693
Informations de copyright
© 2021 The Authors. Journal of Hepato-Biliary-Pancreatic Sciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato-Biliary-Pancreatic Surgery.
Références
Korean J Radiol. 2018 Mar-Apr;19(2):230-236
pubmed: 29520180
Endosc Ultrasound. 2018 Nov-Dec;7(6):404-412
pubmed: 30531024
Gastrointest Endosc. 2017 May;85(5):904-914
pubmed: 28063840
Gastrointest Endosc. 2013 Jul;78(1):91-101
pubmed: 23523301
Am J Gastroenterol. 2018 Jul;113(7):987-997
pubmed: 29961772
J Hepatobiliary Pancreat Sci. 2021 Dec;28(12):1130-1137
pubmed: 34118136
J Gastrointest Surg. 2019 Jan;23(1):192-198
pubmed: 30128830
Dig Dis Sci. 2012 Apr;57(4):1056-63
pubmed: 22101941
J Hepatobiliary Pancreat Sci. 2019 Jul;26(7):249-269
pubmed: 31025816
Gastrointest Endosc. 2009 Aug;70(2):317-21
pubmed: 19539920
Gastrointest Endosc. 2020 Sep;92(3):623-631.e1
pubmed: 32278705
Gastrointest Endosc. 2010 Mar;71(3):446-54
pubmed: 20189503
J Clin Gastroenterol. 2015 Oct;49(9):764-70
pubmed: 25518004
J Gastroenterol Hepatol. 2020 Jul;35(7):1201-1207
pubmed: 31830336
Therap Adv Gastroenterol. 2017 Jan;10(1):42-53
pubmed: 28286558
Gastrointest Endosc. 2015 Dec;82(6):993-1001
pubmed: 26384159
Gastrointest Endosc. 2019 Oct;90(4):663-672.e2
pubmed: 31220446
Endoscopy. 2018 Sep;50(9):910-930
pubmed: 30086596